Hisoar Pharmaceutical Overview
- Year Founded
-
1966
- Status
-
Public
- Employees
-
2,736
- Stock Symbol
-
002099
- Investments
-
2
- Share Price
-
$0.84
- (As of Friday Closing)
Hisoar Pharmaceutical General Information
Description
Zhejiang Hisoar Pharmaceutical Co Ltd is engaged in Production and sales of specialty intermediates, active pharmaceutical ingredients and related preparations.
Contact Information
Website
www.hisoar.comCorporate Office
- No. 100, Waisha Branch Road, Jiaojiang District
- Taizhou, Zhejiang
- China
Corporate Office
- No. 100, Waisha Branch Road, Jiaojiang District
- Taizhou, Zhejiang
- China
Hisoar Pharmaceutical Stock Performance
As of 13-Nov-2026, Hisoar Pharmaceutical’s stock price is $0.84. Its current market cap is $1.36B with 1.62B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.84 | $0.86 | $0.72 - $1.31 | $1.36B | 1.62B | 22M | -$0.02 |
Hisoar Pharmaceutical Financials Summary
As of 30-Sep-2026, Hisoar Pharmaceutical has a trailing 12-month revenue of $295M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,513,635 | 1,413,969 | 1,093,910 | 1,557,310 |
| Revenue | 294,624 | 258,742 | 270,152 | 306,986 |
| EBITDA | (33,509) | 32,474 | (2,951) | (18,656) |
| Net Income | (34,021) | (12,665) | (46,027) | (59,373) |
| Total Assets | 1,028,421 | 1,048,080 | 1,021,362 | 1,060,871 |
| Total Debt | 184,917 | 184,281 | 169,007 | 148,621 |
Hisoar Pharmaceutical Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Hisoar Pharmaceutical Patents
Hisoar Pharmaceutical Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2024001995-A1 | Lifitegrast morpholine salt, method for preparing same, and use thereof | Inactive | 27-Jun-2022 | ||
| WO-2016115962-A1 | Preparation method for nebivolol intermediate and preparation method for nebivolol | Inactive | 19-Jan-2015 | ||
| WO-2013174035-A1 | Method for preparing anhydrous crystal form i of sitagliptin phosphate | Inactive | 25-May-2012 | ||
| WO-2013097629-A1 | Preparation method of amorolfine hydrochloride | Inactive | 30-Dec-2011 | ||
| EP-2647624-A1 | Intermediates of sitagliptin and preparation process thereof | Active | 03-Dec-2010 | C07C323/25 |
Hisoar Pharmaceutical Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Hisoar Pharmaceutical Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Hisoar Pharmaceutical Investments & Acquisitions (2)
Hisoar Pharmaceutical’s most recent deal was a Later Stage VC with Visum Pharmaceutical for . The deal was made on 25-Aug-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Visum Pharmaceutical | 25-Aug-2021 | Later Stage VC | Drug Discovery | ||
| Taizhou Qianjin Chemicals | 01-Oct-2014 | Merger/Acquisition | Other Commercial Services |
Hisoar Pharmaceutical ESG
Risk Overview
Risk Rating
Updated November, 30, 2024
41.78 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,271
Rank
Percentile
Pharmaceuticals
Industry
of 908
Rank
Percentile
Pharmaceuticals
Subindustry
of 406
Rank
Percentile
Hisoar Pharmaceutical FAQs
-
When was Hisoar Pharmaceutical founded?
Hisoar Pharmaceutical was founded in 1966.
-
Where is Hisoar Pharmaceutical headquartered?
Hisoar Pharmaceutical is headquartered in Taizhou, China.
-
What is the size of Hisoar Pharmaceutical?
Hisoar Pharmaceutical has 2,736 total employees.
-
What industry is Hisoar Pharmaceutical in?
Hisoar Pharmaceutical’s primary industry is Pharmaceuticals.
-
Is Hisoar Pharmaceutical a private or public company?
Hisoar Pharmaceutical is a Public company.
-
What is Hisoar Pharmaceutical’s stock symbol?
The ticker symbol for Hisoar Pharmaceutical is 002099.
-
What is the current stock price of Hisoar Pharmaceutical?
As of 13-Nov-2026 the stock price of Hisoar Pharmaceutical is $0.84.
-
What is the current market cap of Hisoar Pharmaceutical?
The current market capitalization of Hisoar Pharmaceutical is $1.36B.
-
What is Hisoar Pharmaceutical’s current revenue?
The trailing twelve month revenue for Hisoar Pharmaceutical is $295M.
-
What is Hisoar Pharmaceutical’s annual earnings per share (EPS)?
Hisoar Pharmaceutical’s EPS for 12 months was -$0.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
